A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Key Inclusion Criteria:

1. Written informed consent to participate

2. At least 18 years of age

3. High and very high risk patients as assessed by the physician suffering fromdocumented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoicacid treatment

4. Patients treated with:

• bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,

• bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,

• bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe

• initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatinsimultaneously

6. Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) Anuntreated LDL-C value must be available within 5 years prior to the start of thetriple therapy. Untreated means that the LDL-C value is not influenced by any lipidlowering therapy at the time of blood collection. Time window for not being treatedas specified in the protocol.

7. No contraindications exist according to the SmPC of bempedoic acid, the respectivestatin and ezetimibe as per physicians' assessment 9) No concurrent participation inan interventional study (simultaneous participation in other non-interventionalstudies is possible) 10) Life expectancy > 1 -year

Key Exclusion Criteria:

1. Patients who have received PCSK9i monoclonal antibody treatment in the last 3 monthsbefore the start of the triple therapy exposure

2. Patients who have ever received PCSK9i-siRNA treatment